Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). The biotech has decided to seek ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

In August, Trevena underwent a reverse stock split, a move often enacted when a company’s share price dips too low. The split wasn’t enough to stave off delisting, with Nasdaq removing Trevena’s stock ...

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed ...

Sarepta Therapeutics has ended development of a late-phase Duchenne muscular dystrophy (DMD) drug candidate over a safety problem. The safety signal deprived Sarepta of a near-term shot at accelerated ...

California VC firm Aditum Bio is reaching across the Pacific to hatch a brand-new biotech. Teaming up with China-based Leads ...

Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

Viracta Therapeutics is implementing its second round of layoffs in just three months as the cash-strapped biotech tries to keep funds flowing to its lymphoma program. | Viracta Therapeutics is ...

Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...